This editorial discusses a new drug targeting aldosterone synthase for the treatment of resistant hypertension.
Components of the renin–angiotensin–aldosterone pathway are targets for drugs to control resistant hypertension. This editorial describes a new drug targeting aldosterone synthase.
No takes yet. Share an insight, caveat, or question.
Leopold et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: